醫療團隊
專業的醫護人員,提供最佳的醫療服務
醫師介紹
張國欽醫師
一般消化系統疾病診治、病毒性肝炎診治、肝硬化肝衰竭診治、肝癌藥物治療、診斷性超音波、介入性超音波診治、肝腫瘤消融治療、消化性潰瘍疾病、內視鏡診治、發炎性腸道疾病診治
- 國語,英語,閩南語
- 助理教授
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
-
現職
- 高雄長庚紀念醫院 副教授級主治醫師
- 長庚大學醫學系 兼任助理教授
- 中華民國醫用超音波學會第19屆理事(202210~202410)
-
學歷
- 高雄醫學大學學士後醫學系畢
-
經歷
- 高雄長庚醫院內科部住院醫師
- 高雄長庚醫院胃腸肝膽科系研究員
- 鳳山醫院胃腸肝膽科系主治醫師
- 高雄長庚紀念醫院 內科部副部主任 (2016.07~2019.06)
-
學會與認證
- 台灣內科醫學會內科專科醫師及指導醫師
- 台灣消化系醫學會消化系內科專科醫師及指導醫師
- 台灣消化系內視鏡醫學會消化系內視鏡專科醫師及指導醫師
- 中華民國醫用超音波學會超音波專業醫師
- 台灣肝癌醫學會專科醫師
- 台灣腫瘤消融學會認證肝腫瘤消融手術醫師
- 台灣醫學教育學會一般醫學師資
-
論文及期刊發表
- Chang KC, Lin MT, Wang JH, Hung CH, Chen CH, Chiu SY*, Hu TH*. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral. Viruses. 2022 Nov 29;14(12):2671. (SCI)
B型肝炎核心相關抗原可預測接受長期口服抗病毒藥物治療的慢性B型肝炎肝硬化患者發生肝癌之風險 - Hu TH, Yueh-Hsia Chiu S, Tseng PL, Chen CH, Lu SN, Wang JH, Hung CH, Kee KM, Lin MT, Chang KC*, Lin MC, Chien RN*. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naive patients with chronic hepatitis B-related compensated cirrhosis in Taiwan. Aliment Pharmacol Ther. 2020 Dec;52(11-12):1695-1706. (SCI)
使用貝樂克或惠立妥治療慢性B型肝炎代償性肝硬化患者之五年發生肝癌之風險比較 - Chang KC*, Ye YH, Wu CK, Lin MT, Tsai MC, Tseng PL, Hu TH. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. J Formos Med Assoc. 2018 Nov;117(11):1011-1018. (SCI)
慢性C型肝炎病人接受長效型干擾素合併RIBAVIRIN未達病毒清除發生肝癌之危險因子 - Chang KC, Tseng PL, Wu YY, Hung CH, Huang CM, Lu SN, Wang JH, Lee CM, Chen CH, Tsai MC, Yen YH, Lin MT, Wu CK, Huang CC, Chen HH, Hu TH*. A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2015 May;13(5):1017-24. (SCI)
IFNL3多型性為C型肝炎治療後發生肝癌之獨立預測因子 - Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH*. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer. 2013 Oct 29;109(9):2481-8. (SCI)
慢性C型肝炎病人經干擾素治療後預測發生肝癌風險之臨床指引 - Lin SC, Chuah SK, Wu KL, Chiu KW, Chang KC*, Chiu YC, Chou YP, Hu ML, Tai WC, Chiou SS, Hu TH, Changchien CS. Endoscopic management of adult foreign bodies in the upper-GI tract:clinical experiences at a tertiary hospital in Southern Taiwan. Gastroenterol J Taiwan 2012 Dec; 29(4): 326-333.
成人上消化道異物的內視鏡處理:南台灣醫學中心之臨床經驗 - Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, Yen MF, Lin SC, Yen YH, Tsai MC, Tseng PL, Hu TH*. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother. 2012 Nov;67(11):2766-72. (SCI)
慢性C型肝炎病患接受長效型干擾素及雷巴威林合併治療癒後之新的發生肝癌預測計分方法 - Chang KC, Lu SN, Chen PF, Hung CH, Kee KM, Yen YH, Wang JH*. Incidence and associated risk factors of hepatocellular carcinoma in a dural hepatitis B and C virus endemic area: a surveillance study. Kaohsiung J Med Sci. 2011 Mar;27(3):85-90. (SCI)
肝癌高危險群之肝癌發生率及其相關因子:B、C型肝炎高盛行社區研究 - Chang KC, Tsai PS, Hsu MC, Hung SF, Tsai CC, Lu SN*. Chronic hepatitis C increased the mortality rates of patients with hepatocellular carcinoma and diabetes mellitus in a triple hepatitis virus endemic community. J Gastroenterol. 2010 Jun;45(6):636-45. (SCI)
在一個三種類型肝炎病毒盛行的社區裡,慢性C型肝炎增加肝細胞癌和糖尿病病人之死亡率 - Chang KC, Tai MH, Lin JW, Wang CC, Huang CC, Hung CH, Chen CH, Lu SN, Lee CM, Changchien CS, Hu TH*. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer. 2007 Sep 1;121(5):1059-65. (SCI)
肝癌衍生生長因子為胃腸道基質瘤新的預後因子 - Chang KC, Chuah SK, Changchien CS, Tsai TL, Lu SN, Chiu YC, Chen YS, Wang CC, Lin JW, Lee CM, Hu TH*. Clinical characteristics and prognostic factors of splenic abscess: a review of 67 cases in a single medical center of Taiwan. World J Gastroenterol. 2006 Jan 21;12(3):460-4. (SCI)
脾臟膿瘍之臨床特徵和預後因子-台灣單一醫學中心67病例回顧 - Chang KC, Changchien CS, Kuo CM, Chiu YC, Chuah SK, Chiu KW, Kuo CH*. Clinical analysis of the efficacy in Lipase/Amylase ratio for acute pancreatitis. J Int Med Taiwan. 2005; 16(3): 113-120.
台灣地區急性胰臟炎病患之LIPASE/AMYLASE之比值之臨床意義分析
- Chang KC, Lin MT, Wang JH, Hung CH, Chen CH, Chiu SY*, Hu TH*. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral. Viruses. 2022 Nov 29;14(12):2671. (SCI)